|
Activity Number:
|
394
- Population Diversity Considerations in Clinical Trials
|
|
Type:
|
Invited
|
|
Date/Time:
|
Thursday, August 12, 2021 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Health Policy Statistics Section
|
|
Abstract #316945
|
|
|
Title:
|
Diversity and Inclusion in Clinical Trials
|
|
Author(s):
|
Rajaa Nahra and Claudia Cabrera*
|
|
Companies:
|
AstraZeneca and AstraZeneca
|
|
Keywords:
|
diversity;
clinical trials;
inclusion;
underrepresented
|
|
Abstract:
|
It is well established that minorities and women remain underrepresented in clinical trials to develop new drugs and medical devices. Achieving greater diversity in clinical trial participation has been gaining significant momentum and is the focus of various organizations and institutions. Diversity and inclusion in clinical trials could enhance biomedical science and healthcare by uncovering differences that may be important for the safe and effective use of therapies. Lack of diversity in clinical trials creates a moral, scientific, and medical problem. Multiple stakeholders must work together to identify and address barriers to inclusion of diverse populations in order to achieve meaningful change.
|
Authors who are presenting talks have a * after their name.
